G1 Therapeutics, Inc. Common Stock
GTHX
GTHX was delisted on the 17th of September, 2024.
108 hedge funds and large institutions have $271M invested in G1 Therapeutics, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 41 increasing their positions, 35 reducing their positions, and 18 closing their positions.
17% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 35
5% less call options, than puts
Call options by funds: $1.07M | Put options by funds: $1.13M
6% less funds holding
Funds holding: 115 → 108 (-7)
24% less capital invested
Capital invested by funds: $358M → $271M (-$87.2M)
33% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fisher Asset Management
Camas,
Washington
|
+$6.75M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$3.16M |
| 3 |
CA
CHI Advisors
New York
|
+$2.29M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$1.75M |
| 5 |
Rafferty Asset Management
New York
|
+$1.74M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$8.77M |
| 2 |
Goldman Sachs
New York
|
-$3.87M |
| 3 |
Voloridge Investment Management
Jupiter,
Florida
|
-$2.65M |
| 4 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$2.56M |
| 5 |
Russell Investments Group
London,
United Kingdom
|
-$2.1M |
GTHX Hedge Fund Activity: Q4 2021 in Review
108 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in G1 Therapeutics, Inc. Common Stock (GTHX) for Q4 2021, worth a combined $271M — down 24% from $358M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of GTHX and 12 opened new positions — a net loss of 6 holders — while 35 trimmed existing stakes and 41 added.
The largest buyer was Fisher Asset Management, adding an estimated $6.75M. The largest seller was Fidelity Investments, cutting an estimated $8.77M.
- 108 institutional investors held G1 Therapeutics, Inc. Common Stock (GTHX) as of Q4 2021, down from 115 in Q3 2021.
- Funds reported $271M of G1 Therapeutics, Inc. Common Stock stock for Q4 2021, down 24% quarter-over-quarter.
- 12 funds opened new G1 Therapeutics, Inc. Common Stock positions in Q4 2021 and 18 closed out, a net change of -6 holders.
- The largest G1 Therapeutics, Inc. Common Stock buyer in Q4 2021 was Fisher Asset Management, an estimated $6.75M added.
- The largest G1 Therapeutics, Inc. Common Stock seller in Q4 2021 was Fidelity Investments, an estimated $8.77M sold.
Based on aggregated 13F filings for Q4 2021.